Messerly 7-23

Medicare’s ability to negotiate drug prices as part of the Inflation Reduction Act could be another focus for a Harris presidency — and a concern for much of the pharmaceutical industry. “It’s likely something she can tout as an achievement of both hers and Biden’s,” said Lindsay Bealor Greenleaf, head of state and federal policy at the consulting firm ADVI Health, while adding that her policies for implementing drug-related provisions in the IRA could “be more aggressive than the current administration.” One area the industry worries about involves so-called march-in rights, which allow the federal government to seize the patents of some high-cost drugs and create more competition that could lower prices. The Biden administration has yet to wield that power, though it has said it would have the right to.